Mattias Sandström

Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Ivashchenko, Oleksandra V.; O'Doherty, Jim; Hardiansyah, Deni; Cremonesi, Marta et al.

Part of Physica medica (Testo stampato), 2024

• DOI for Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls
• Download full text (pdf) of Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Hindorf, Cecilia; Jessen, Lovisa; Kapidzic, Selma Curkic; Blakkisrud, Johan et al.

Part of Physica medica (Testo stampato), 2023

• DOI for Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

Mínguez Gabiña, Pablo; Sjögreen Gleisner, Katarina; Cremonesi, Marta; Stokke, Caroline et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 2595-2604, 2023

• DOI for Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Gear, Jonathan; Stokke, Caroline; Terwinghe, Christelle; Gnesin, Silvano et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1861-1868, 2023

• DOI for EANM enabling guide: how to improve the accessibility of clinical dosimetry
• Download full text (pdf) of EANM enabling guide: how to improve the accessibility of clinical dosimetry

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Jahn, Ulrika; Garske-Román, Ulrike; Sandström, Mattias; Lubberink, Mark et al.

Part of EJNMMI Research, p. 45, 2023

• DOI for Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
• Download full text (pdf) of Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Ivashchenko, Oleksandra V.; O'Doherty, Jim; Hardiansyah, Deni; Cremonesi, Marta et al.

Part of Physica medica (Testo stampato), 2024

• DOI for Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls
• Download full text (pdf) of Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls

Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Hindorf, Cecilia; Jessen, Lovisa; Kapidzic, Selma Curkic; Blakkisrud, Johan et al.

Part of Physica medica (Testo stampato), 2023

• DOI for Traceable calibration with ¹⁷⁷Lu and comparison of activity meters at hospitals in Norway and Sweden

Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

Mínguez Gabiña, Pablo; Sjögreen Gleisner, Katarina; Cremonesi, Marta; Stokke, Caroline et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 2595-2604, 2023

• DOI for Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Gear, Jonathan; Stokke, Caroline; Terwinghe, Christelle; Gnesin, Silvano et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1861-1868, 2023

• DOI for EANM enabling guide: how to improve the accessibility of clinical dosimetry
• Download full text (pdf) of EANM enabling guide: how to improve the accessibility of clinical dosimetry

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Jahn, Ulrika; Garske-Román, Ulrike; Sandström, Mattias; Lubberink, Mark et al.

Part of EJNMMI Research, p. 45, 2023

• DOI for Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
• Download full text (pdf) of Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Part of Neuroendocrinology, p. 330-343, 2021

• DOI for 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Download full text (pdf) of 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE: Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Lubberink, Mark et al.

Part of Cancers, 2021

• DOI for Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE: Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
• Download full text (pdf) of Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE: Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

Bragina, Olga; von Witting, Emma; Garousi, Javad; Zelchan, Roman et al.

Part of Journal of Nuclear Medicine, p. 493-499, 2021

• DOI for Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Garske-Román, Ulrike et al.

Part of Neuroendocrinology, p. 662-670, 2020

• DOI for ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors

Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE.

Ilan, Ezgi; Velikyan, Irina; Sandström, Mattias; Sundin, Anders et al.

Part of Journal of Nuclear Medicine, p. 217-221, 2020

• DOI for Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE.

Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Sandström, Mattias; Freedman, Nanette; Fröss-Baron, Katarzyna; Khan, Tanweera et al.

Part of EJNMMI Physics, 2020

• DOI for Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
• Download full text (pdf) of Kidney dosimetry in 777 patients during ¹⁷⁷Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Personalized radiation dosimetry for PRRT: how many scans are really required?

Freedman, Nanette; Sandström, Mattias; Kuten, Jonathan; Shtraus, Natan et al.

Part of EJNMMI Physics, 2020

• DOI for Personalized radiation dosimetry for PRRT: how many scans are really required?
• Download full text (pdf) of Personalized radiation dosimetry for PRRT: how many scans are really required?

In vivo instability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Lubberink, Mark; Wilking, Helena; Öst, Amalia; Ilan, Ezgi et al.

Part of Journal of Nuclear Medicine, p. 1337-1340, 2020

• DOI for In vivo instability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

Vyakaranam, Achyut Ram; Crona, Joakim; Norlén, Olov; Granberg, Dan et al.

Part of Cancers, 2019

• DOI for Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.
• Download full text (pdf) of Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with ¹⁷⁷Lu-DOTATATE.

Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3

Vorobyeva, Anzhelika; Schulga, Alexey; Konovalova, Elena; Guler, Rezan et al.

Part of Scientific Reports, 2019

• DOI for Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3
• Download full text (pdf) of Optimal composition and position of histidine-containing tags improves biodistribution of Tc-99m-labeled DARP in G3

Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

Sandström, Mattias; Garske, Ulrike; Johansson, Silvia; Granberg, Dan et al.

Part of Acta Oncologica, p. 516-521, 2018

• DOI for Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

In-vivo stability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Wilking, H.; Ilan, Ezgi; Sandström, Mattias; Andersson, C. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI for In-vivo stability of ¹⁷⁷Lu-DOTATATE during peptide receptor radionuclide therapy

Image contrast of ¹⁷⁷Lu-filled spheres as measured with a GE Discovery 670 CZT SPECT/CT system

Sandström, Mattias; Sundin, Anders; Lubberink, Mark; Ljungberg, M.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI for Image contrast of ¹⁷⁷Lu-filled spheres as measured with a GE Discovery 670 CZT SPECT/CT system

Comparison of Ga-68-DOTATATE and Lu-177-DOTATATE kinetics in neuroendocrine tumors

Ilan, Ezgi; Lubberink, Mark; Sandström, Mattias; Jahn, Ulrika et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

Sandström, Mattias; Fröss-Baron, Katarzyna; Khan, Tanweera Shaheena; Granberg, Dan et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI for Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving ¹⁷⁷Lu-DOTATATE therapy

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors

Jahn, Ulrika; Ilan, Ezgi; Sandström, Mattias; Garske-Román, Ulrike et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 970-988, 2018

• DOI for Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Download full text (pdf) of Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Ilan, Ezgi; Sandström, Mattias; Velikyan, Irina; Sundin, Anders et al.

Part of Journal of Nuclear Medicine, p. 744-749, 2017

• DOI for Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Sjögreen Gleisner, Katarina; Spezi, Emiliano; Solny, Pavel; Minguez Gabina, Pablo et al.

Part of EJNMMI Physics, 2017

• DOI for Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
• Download full text (pdf) of Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force

Stokke, Caroline; Gabina, Pablo Minguez; Solny, Pavel; Cicone, Francesco et al.

Part of EJNMMI Physics, 2017

• DOI for Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
• Download full text (pdf) of Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force

Low tracer availability of Ga-68-DOTATOC and Ga-68-DOTATATE in blood for patients with high SSTR density leads to non-linear correlation between SUV and K-i

Ilan, Ezgi; Sundin, Anders; Velikyan, Irina; Sandström, Mattias et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2017

Gender-related differences in absorbed dose to risk organs in patients receiving Lu-177-Octreotate therapy

Sandström, Mattias; Ilan, Ezgi; Fröss-Baron, Katarzyna; Garske, Ulrike et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2017

Image quality measurements with ¹⁷⁷Lu on a GE Discovery 670 CZT

Sandström, Mattias; Ilan, Ezgi; Sundin, Anders; Lubberink, Mark

Part of Journal of Nuclear Medicine, 2017

Is there a gender difference of absorbed dose to the risk organs in patients receiving ¹⁷⁷Lu-Octreotate therapy?

Sandström, Mattias; Ilan, Ezgi; Sundin, Anders; Lubberink, Mark

Part of Journal of Nuclear Medicine, 2017

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Sörensen, Jens; Velikyan, Irina; Sandberg, Dan; Wennborg, Anders et al.

Part of Theranostics, p. 262-271, 2016

• DOI for Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
• Download full text (pdf) of Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

Honarvar, Hadis; Westerlund, Kristina; Altai, Mohamed; Sandström, Mattias et al.

Part of Theranostics, p. 93-103, 2016

• DOI for Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
• Download full text (pdf) of Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases

Ebeling Barbier, Charlotte; Garske-Román, Ulrike; Sandström, Mattias; Nyman, Rickard et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1425-1431, 2016

• DOI for Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases

Comparison of PET/CT and PET/MR-based Ga-68-DOTATOC standardized uptake values

Ilan, Ezgi; Sundin, Anders; Velikyan, Irina; Sandström, Mattias et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2016

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

Sandström, Mattias; Lindskog, Karolina; Velikyan, Irma; Wennborg, Anders et al.

Part of Journal of Nuclear Medicine, p. 867-871, 2016

• DOI for Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers

Garousi, Javad; Lindbo, Sarah; Nilvebrant, Johan; Åstrand, Mikael et al.

Part of Cancer Research, p. 4364-4371, 2015

• DOI for ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers

Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE

Ilan, Ezgi; Sandström, Mattias; Wassberg, Cecilia; Sundin, Anders et al.

Part of Journal of Nuclear Medicine, p. 177-182, 2015

• DOI for Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE

Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.

Sandström, Mattias; Ilan, Ezgi; Karlberg, Anna; Johansson, Silvia et al.

Part of EJNMMI Physics, 2015

• DOI for Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.
• Download full text (pdf) of Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.

Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

Mitran, Bogdan; Altai, Mohamed; Hofström, Camilla; Honarvar, Hadis et al.

Part of Amino Acids, p. 303-15, 2015

• DOI for Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression
• Download full text (pdf) of Evaluation of (99m)Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Andersson, Ken G.; Rosestedt, Maria; Varasteh, Zohreh; Malm, Magdalena et al.

Part of Oncology Reports, p. 1042-1048, 2015

• DOI for Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors
• Download full text (pdf) of Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Non-invasive determination of HER2-expression in metastatic breast cancer by using Ga-68-ABY025 PET/CT.

Lindman, Henrik; Wennborg, Anders; Velikyan, Irina; Feldwisch, Joachim et al.

Part of Journal of Clinical Oncology, 2015

Accuracy of [Ga-68]ABY-025 PET/CT for determination of HER2-expression in metastatic breast cancer

Sörensen, Jens; Velikyan, Irina; Wennborg, Anders; Feldwisch, Joachim et al.

Part of Journal of Nuclear Medicine, 2015

Validation of parametric net influx rate images of Ga-68-DOTATOC and Ga-68-DOTATATE

Ilan, Ezgi; Sandström, Mattias; Velikyan, Irina; Sundin, Anders et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2015

Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors

Ebeling-Barbier, Charlotte; Garske-Roman, Ulrike; Antonodimitrakis, Pantelis; Sandström, Mattias et al.

Part of Neuroendocrinology, p. 136-137, 2015

• DOI for Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors

Feasibility of Affibody molecule-based PNA-mediated pretargeting

Honarvar, Hadis; Westerlund, K.; Altai, Mohamed; Sandstrom, Mattias et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2015

Fractional contribution of extrapolations after 96 h in absorbed dose calculation to kidneys in 450 patients with neuroendocrine tumours receiving Lu-177-DOTATATE therapy

Sandström, Mattias; Garske-Roman, Ulrike; Granberg, Dan; Sundin, Anders et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2015

Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting: proof-of-principle

Altai, Mohamed; Tsourma, M.; Mitran, Bogdan; Honarvar, Hadis et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2015

111In-labeled NOTA-conjugated Affibody molecules for visualization of HER3 expression in malignant tumors

Andersson, K. G.; Varasteh, Zohreh; Rosestedt, Maria; Malm, M. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination: first-in-man

Velikyan, Irina; Wennborg, A.; Feldwisch, J.; Orlova, Anna et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Development of ADAPT6 as a new scaffold protein for radionuclide molecular imaging

Garousi, Javad; Lindbo, S.; Orlova, Anna; Astrand, M. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Radiation dosimetry and tracer kinetic analysis of Ga-68-ABY025 Affibody in breast cancer patients

Lubberink, Mark; Lindskog, K.; Sandström, Mattias; Velikyan, Irina et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Favourable outcome after 177Lu-DOTA-octreotate therapy of patients with neuroendocrine of the rectum -an update

Garske-Roman, Ulrike E.; Sandström, Mattias; Johansson, Silvia; Fröss-Baron, Katarzyna et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT

Sörensen, Jens; Velikyan, Irina; Wennborg, A.; Feldwisch, J. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Comparison of [68Ga]-DOTA-TOC and [68Ga]-DOTA-TATE: Aspects on quantification in neuroendocrine tumour therapy monitoring

Sundin, Anders; Velikyan, Irina; Sörensen, Jens; Garske-Roman, Ulrike et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment

Altai, Mohamed; Wållberg, Helena; Honarvar, Hadis; Strand, Joanna et al.

Part of Journal of Nuclear Medicine, p. 1842-1848, 2014

• DOI for ¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment
• Download full text (pdf) of ¹⁸⁸Re-Z_HER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Velikyan, Irina; Sundin, Anders; Sörensen, Jens; Lubberink, Mark et al.

Part of Journal of Nuclear Medicine, p. 204-10, 2014

• DOI for Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification.

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re

Altai, Mohamed; Honarvar, Hadis; Wållberg, Helena; Strand, Joanna et al.

Part of European Journal of Medicinal Chemistry, p. 519-528, 2014

• DOI for Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re
• Download full text (pdf) of Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with ¹⁸⁸Re

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule

Sörensen, Jens; Sandberg, Dan; Sandström, Mattias; Wennborg, Anders et al.

Part of Journal of Nuclear Medicine, p. 730-735, 2014

• DOI for First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule
• Download full text (pdf) of First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

Sandström, Mattias; Garske-Román, Ulrike; Granberg, Dan; Johansson, Silvia et al.

Part of Journal of Nuclear Medicine, p. 33-41, 2013

• DOI for Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

[^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

Orlova, Anna; Hofström, Camilla; Strand, Joanna; Varasteh, Zohreh et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 439-449, 2013

• DOI for [^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours
• Download full text (pdf) of [^99mTc(CO)₃]⁺-(HE)₃-Z_IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

Varasteh, Zohreh; Åberg, Ola; Velikyan, Irina; Lindeberg, Gunnar et al.

Part of PLOS ONE, 2013

• DOI for In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
• Download full text (pdf) of In Vitro and In Vivo Evaluation of a F-18-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging

Varasteh, Zohreh; Velikyan, Irina; Lindeberg, Gunnar; Sörensen, Jens et al.

Part of Bioconjugate chemistry, p. 1144-1153, 2013

• DOI for Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging
• Download full text (pdf) of Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging

Comparison of radiation dosimetry of [Ga-68]Ga-DOTA-TOC and [Ga-68]Ga-DOTA-TATE in patients affected by neuroendocrine tumours

Velikyan, Irina; Sandström, Mattias; Garske, Ulrike; Sörensen, Jens et al.

Part of Journal of labelled compounds & radiopharmaceuticals, 2013

Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

Sandström, Mattias; Velikyan, Irina; Garske-Roman, Ulrike; Sörensen, Jens et al.

Part of Journal of Nuclear Medicine, p. 1755-1759, 2013

• DOI for Comparative Biodistribution and Radiation Dosimetry of Ga-68-DOTATOC and Ga-68-DOTATATE in Patients with Neuroendocrine Tumors

GRPR antagonist NOTA-P2-RM26 labeled with fluorine-18: radiochemistry, in vitro and in vivo evaluation

Varasteh, Zohreh; Åberg, Ola; Lindberg, G.; Antoni, Gunnar et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2013

Biological effective doses in 300 patients undergoing therapy with Lu-177-octreotate

Sandström, Mattias; Garske-Roman, Ulrike; Granberg, Dan; Eriksson, B. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2013

Selection of an optimal cysteine-containing peptide-based chelator for labeling of Affibody molecules with 188-Re

Altai, Mohamed; Honarvar, Hadis; Wållberg, Helena; Strand, Joanna et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2013

• DOI for Selection of an optimal cysteine-containing peptide-based chelator for labeling of Affibody molecules with 188-Re

Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Granberg, Dan et al.

Part of Theranostics, p. 459-471, 2012

• DOI for Lessons on Tumour Response: Imaging during Therapy with Lu-177-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹In using a maleimido derivative of NODAGA

Altai, Mohamed; Perols, Anna; Eriksson Karlström, Amelie; Sandström, Mattias et al.

Part of Nuclear Medicine and Biology, p. 518-529, 2012

• DOI for Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with ¹¹¹In using a maleimido derivative of NODAGA

Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging

Rosik, Daniel; Orlova, Anna; Malmberg, Jennie; Altai, Mohamed et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 693-702, 2012

• DOI for Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Malmberg, Jennie; Perols, Anna; Varasteh, Zohreh; Altai, Mohamed et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 481-492, 2012

• DOI for Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_IGF1R:4551

Tolmachev, Vladimir; Malmberg, Jennie; Hofström, Camilla; Abrahmsén, Lars et al.

Part of Journal of Nuclear Medicine, p. 90-97, 2012

• DOI for Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule ¹¹¹In-DOTA-Z_IGF1R:4551

Regional Lung Perfusion estimated by Electrical Impedance Tomography in a piglet model of lung collapse

Borges, João Batista; Suarez-Sipmann, Fernando; Bohm, Stephan H; Tusman, Gerardo et al.

Part of Journal of applied physiology, p. 225-236, 2011

• DOI for Regional Lung Perfusion estimated by Electrical Impedance Tomography in a piglet model of lung collapse

Ventilation Distribution Studies Comparing Technegas and "Gallgas" Using (GaCl3)-Ga-68 as the Label

Borges, João Batista; Velikyan, Irina; Långström, Bengt; Sörensen, Jens et al.

Part of Journal of Nuclear Medicine, p. 206-209, 2011

• DOI for Ventilation Distribution Studies Comparing Technegas and "Gallgas" Using (GaCl3)-Ga-68 as the Label

Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate

Tolmachev, Vladimir; Feldwisch, Joachim; Lindborg, Malin; Baastrup, Barbro et al.

Part of Nuclear Medicine and Biology, p. 697-706, 2011

• DOI for Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate

Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules

Tolmachev, Vladimir; Altai, Mohamed; Sandström, Mattias; Perols, Anna et al.

Part of Bioconjugate chemistry, p. 894-902, 2011

• DOI for Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

Tolmachev, Vladimir; Wållberg, Helena; Sandström, Mattias; Hansson, Monika et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 531-539, 2011

• DOI for Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels

Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

Garske, Ulrike; Sandström, Mattias; Johansson, Silvia; Sundin, Anders et al.

Part of Acta Oncologica, p. 86-96, 2011

• DOI for Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on (111)In- and (125)I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody

Malmberg, Jennie; Sandström, Mattias; Wester, Kenneth; Tolmachev, Vladimir et al.

Part of Nuclear Medicine and Biology, p. 1093-1102, 2011

• DOI for Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on (111)In- and (125)I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody

Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

Ahlgren, Sara; Orlova, Anna; Wållberg, Helena; Hansson, Monika et al.

Part of Journal of Nuclear Medicine, p. 1131-1138, 2010

• DOI for Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold

A HER2-binding Affibody molecule labelled with ⁶⁸Ga for PET imaging: direct in vivo comparison with the ¹¹¹In-labelled analogue

Tolmachev, Vladimir; Velikyan, Irina; Sandström, Mattias; Orlova, Anna

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1356-1367, 2010

• DOI for A HER2-binding Affibody molecule labelled with ⁶⁸Ga for PET imaging: direct in vivo comparison with the ¹¹¹In-labelled analogue

Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Sandström, Mattias; Garske, Ulrike; Granberg, Dan; Sundin, Anders et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 212-225, 2010

• DOI for Individualized dosimetry in patients undergoing therapy with Lu-177-DOTA-D-Phe(1)-Tyr(3)-octreotate

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

Tolmachev, Vladimir; Friedman, Mikaela; Sandström, Mattias; Eriksson, Tove L. et al.

Part of Journal of Nuclear Medicine, p. 274-283, 2009

• DOI for Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Tolmachev, Vladimir; Orlova, Anna; Pehrson, Rikard; Galli, Joakim et al.

Part of Cancer Research, p. 2773-2782, 2007

• DOI for Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

Orlova, Anna; Tolmachev, Vladimir; Pehrson, Rikard; Lindborg, Malin et al.

Part of Cancer Research, p. 2178-2186, 2007

• DOI for Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand

Tran, Thuy; Orlova, Anna; Sivaev, Igor; Sandström, Mattias et al.

Part of International Journal of Molecular Medicine, p. 485-493, 2007

Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM.

Razifar, Pasha; Sandström, Mattias; Schneider, Harald; Långström, Bengt et al.

Part of Bio Medical Central (BMC): Medical Imaging, 2005

• DOI for Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM.

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Persson, Mikael; Tolmachev, Vladimir; Andersson, Karl; Gedda, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1457-62, 2005

• DOI for [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

Sandström, Mattias; Tolmachev, Vladimir; Kairemo, Kalevi; Lundqvist, Hans et al.

Part of Physics in Medicine and Biology, p. 5419-32, 2004

• DOI for Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

Comparison of ⁶⁸Ga-DOTATATE and ¹⁷⁷Lu-DOTATATE kinetics in neuroendocrine tumors

Ilan, Ezgi; Velikyan, Irina; Sandström, Mattias; Andersson, Camilla et al.

Dosimetry of Radionuclide Therapy with ¹⁷⁷Lu-octreotate

Sandström, Mattias

2011

• Download full text (pdf) of Dosimetry of Radionuclide Therapy with ¹⁷⁷Lu-octreotate